-
Innovation Ranking
Innovation Ranking – Swedish Match AB
Swedish Match AB (Swedish Match) is a tobacco manufacturing company that produces and sells cigars and smokeless tobacco products. The company’s product portfolio comprises snuff, snus, cigars, chewing tobacco, pipe tobacco, lighters, matches, and other related products. It sells products under Ettan, Longhorn, Nick and Johnny, The Lab, Goteborgs Rape, Catch, Kronan, Timber Wolf, America’s Best Chew, Kaliber, General, White Owl, Solstickan, Redheads, Nitedals, Garcia y Vega, Thunder, Oliver Twist, and Cricket brands. Swedish Match offers disposable razors, batteries, and...
-
Innovation Ranking
Innovation Ranking – Match Group Inc
Match Group Inc (Match Group) is a provider of internet-based dating apps. The company creates compatible matches based on traits that are scientifically proven to predict meaningful relationships. It owns and operates a portfolio of brands such as Match, Tinder, Meetic, Pairs, PlentyOfFish, OkCupid, Azar, Chispa, OurTime, Hinge, and Hakuna, among others. The company provides its dating services in different languages and is accessible through various technologies such as wearables, tablets, smartphone applications, and desktop websites. It has business presence...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orca-Q in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYT-101 in Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYT-101 in Astrocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYT-101 in Astrocytoma Drug Details: CYT-101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYT-101 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYT-101 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYT-101 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: CYT-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ApoCell in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ApoCell in Osteoarthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ApoCell in Osteoarthritis Drug Details: ApoCell is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabiralizumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabiralizumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabiralizumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Cabiralizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabiralizumab in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabiralizumab in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabiralizumab in Melanoma Drug Details: Cabiralizumab (CSF1R antibody) is under development for...